地高辛使用与当代连续流左心室辅助装置支持患者胃肠道出血的关联
本研究为多中心回顾性队列,纳入649例连续流LVAD患者,评估地高辛使用与胃肠道出血(GIB)的关联。33%患者使用地高辛,校正后地高辛使用与全因GIB发生率降低34%相关(IRR 0.67,95%CI 0.45-0.99,p=0.048),在可能动静脉畸形相关GIB中关联更强(校正IRR 0.47,95%CI 0.25-0.9,p=0.022)。
要点
- 地高辛使用与LVAD患者全因GIB发生率降低34%独立相关。
- 疑诊动静脉畸形相关GIB中,地高辛关联更强(校正IRR 0.47)。
- 需前瞻性数据证实该关联,目前不能确立因果。
核心结论
- 在多中心当代连续流LVAD队列中,地高辛使用与GIB事件减少相关。
- 该关联在疑诊动静脉畸形相关GIB中更强。
- 需前瞻性数据确认此关联。
研究设计与样本
- 多中心回顾性队列分析,纳入两家中心649例连续流LVAD患者。
- GIB事件随访至2年。
- 地高辛使用定义为出院时或LVAD植入后3个月内处方地高辛。
主要发现
- 队列平均年龄57岁(±14),45%(293/649)为桥接移植(BTT)。
- 33%患者使用地高辛。
- 地高辛使用与未校正全因GIB发生率降低32%相关(IRR 0.68,95%CI 0.46-0.99,p=0.049)。
- 校正年龄、性别、INTERMACS分级、肾功能和植入中心后,全因GIB发生率降低34%(IRR 0.67,95%CI 0.45-0.99,p=0.048)。
- 限制于可能动静脉畸形相关GIB时,未校正IRR 0.48(95%CI 0.26-0.89,p=0.02),校正IRR 0.47(95%CI 0.25-0.9,p=0.022)。
临床怎么用
- 对于连续流LVAD患者,地高辛使用可能与较低的GIB风险相关,但需前瞻性验证。
- 临床决策时应综合评估地高辛的获益与风险,不可仅凭此回顾性 association 改变实践。
局限性
- 回顾性研究设计,可能存在未测量混杂。
- 地高辛使用为非随机分配,无法确立因果。
- 仅纳入两家中心数据,外推性受限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Assess the association between digoxin use and gastrointestinal bleeding (GIB) in a multicenter continuous flow left ventricular assist device (LVAD) cohort. METHODS: Patients implanted with continuous flow LVADs with data on GIB and digoxin use from two centers were included in the analysis (n = 649). GIB events were captured up to 2 years of follow-up. Digoxin use was defined as digoxin prescribed at discharge or within the first 3 months after LVAD implantation. A negative binomial regression model was performed to determine the association between digoxin use and number of GIB events over the follow-up period. RESULTS: Mean age of the cohort was 57 years (±14) and 45% (293/649) were bridge to transplant (BTT). Digoxin was prescribed in 33% of patients. Digoxin use was associated with an unadjusted 32% reduction in the incidence of rate of all cause GIB (IRR 0.68, 95% CI 0.46-0.99, p = 0.049). After adjusting for age, sex, Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) profile, renal function, and implanting center there was still a 34% reduction in the incidence rate (IRR 0.67, 95% CI 0.45-0.99, p = 0.048). When limiting the analysis to those with likely arteriovenous malformation associated GIB, the association strengthened (unadjusted: IRR 0.48, 95 % CI 0.26-0.89, p = 0.02, adjusted: IRR 0.47, 95 % CI 0.25-0.9, p = 0.022). CONCLUSIONS: In this multicenter study, inclusive of contemporary devices, digoxin use was associated with reduced GIB events. Prospective data will be required to confirm this association.
引用
- El Rafei A, Trachtenberg BH, Schultz J, et al. Association between digoxin use and gastrointestinal bleeding in contemporary continuous flow left ventricular assist device support. J Heart Lung Transplant. 2021. PMID: 33875331. doi:10.1016/j.healun.2021.03.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。